Study Details

Back to Search Results

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02452632

Astellas Study ID

The unique identification code given by the study sponsor.

1941-CL-2009

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Adult Onset Diabetes

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

19 years - 74 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2015 - Jan 2017

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

143

A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of ASP1941 in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site KR00003

Busan, Republic of Korea

Site KR00016

Seoul, Republic of Korea

Site KR00008

Gangwon-do, Republic of Korea

Site KR00020

Jeollabuk-do, Republic of Korea

Site KR00021

Kyungsangnam-do, Republic of Korea

Site KR00009

Seoul, Republic of Korea

Site KR00017

Seoul, Republic of Korea

Site KR00019

Dong Gu Gwangju, Republic of Korea

Site KR00014

Incheon, Republic of Korea

Site KR00011

Daegu, Republic of Korea

Site KR00004

Seoul, Republic of Korea

Site KR00002

Busan, Republic of Korea

Site KR00012

Seoul, Republic of Korea

Site KR00006

Seoul, Republic of Korea

Site KR00018

Gyeonggi-do, Republic of Korea

Site KR00005

Seoul, Republic of Korea

Site KR00022

Gyeonggi-do, Republic of Korea

Site KR00010

Seoul, Republic of Korea

Site KR00001

Seoul, Republic of Korea

Site KR00013

Seoul, Republic of Korea

Site KR00007

Daegu, Republic of Korea

Site KR00015

Suwon, Republic of Korea

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo